- Home
- MDXH vs MRSN Comparison
MDXH vs MRSN Comparison
Compare MDXH & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDXH | MRSN |
|---|---|---|
| Founded | 2003 | 2001 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 138.8M |
| IPO Year | 2021 | 2017 |
Fundamental Metrics
Financial Performance| Metric | MDXH | MRSN |
|---|---|---|
| Price | $3.53 | $28.51 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $7.67 | ★ $30.38 |
| AVG Volume (30 Days) | ★ 121.8K | 72.4K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $103,069,000.00 | $33,180,000.00 |
| Revenue This Year | $23.34 | N/A |
| Revenue Next Year | $22.98 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 21.68 | N/A |
| 52 Week Low | $1.35 | $5.21 |
| 52 Week High | $5.33 | $37.88 |
Technical Indicators
Market Signals| Indicator | MDXH | MRSN |
|---|---|---|
| Relative Strength Index (RSI) | 50.37 | 75.04 |
| Support Level | $3.20 | $28.85 |
| Resistance Level | $3.58 | $29.15 |
| Average True Range (ATR) | 0.18 | 0.49 |
| MACD | 0.04 | -0.55 |
| Stochastic Oscillator | 85.42 | 48.32 |
Price Performance
Historical ComparisonAbout MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.